



US 20210277073A1

(19) **United States**(12) **Patent Application Publication**  
**JOSELOFF et al.**(10) **Pub. No.: US 2021/0277073 A1**(43) **Pub. Date: Sep. 9, 2021**(54) **KIDNEY DISEASE TARGETS AND USES  
THEREOF***C07K 14/435* (2006.01)*C07K 16/18* (2006.01)*C12Q 1/6876* (2006.01)*G01N 33/53* (2006.01)*C12N 15/113* (2006.01)(71) Applicant: **CELERA CORPORATION**, San Juan  
Capistrano, CA (US)(72) Inventors: **Elizabeth JOSELOFF**, Silver Spring,  
MD (US); **Steve RUBEN**, Brookeville,  
MD (US); **Tao HE**, Acton, MA (US)(52) **U.S. Cl.**CPC ..... *C07K 14/47* (2013.01); *G01N 33/57438*  
(2013.01); *C07K 16/3038* (2013.01); *C12Q*  
*1/6886* (2013.01); *C07K 14/435* (2013.01);  
*C07K 16/18* (2013.01); *A61K 2039/505*  
(2013.01); *G01N 33/53* (2013.01); *C12N*  
*15/113* (2013.01); *G01N 33/57484* (2013.01);  
*Y10T 436/143333* (2015.01); *G01N 2500/00*  
(2013.01); *C12Q 2600/158* (2013.01); *C12Q*  
*1/6876* (2013.01)(21) Appl. No.: **17/143,421**(22) Filed: **Jan. 7, 2021****Related U.S. Application Data**(60) Continuation of application No. 16/210,539, filed on  
Dec. 5, 2018, now abandoned, which is a continuation  
of application No. 15/132,462, filed on Apr. 19, 2016,  
now abandoned, which is a division of application  
No. 14/173,082, filed on Feb. 5, 2014, now aban-  
doned, which is a continuation of application No.  
13/183,696, filed on Jul. 15, 2011, now abandoned,  
which is a division of application No. 12/557,303,  
filed on Sep. 10, 2009, now Pat. No. 7,998,689, which  
is a division of application No. 11/878,050, filed on  
Jul. 20, 2007, now Pat. No. 7,608,413.**Publication Classification**(51) **Int. Cl.***C07K 14/47* (2006.01)*G01N 33/574* (2006.01)*C07K 16/30* (2006.01)*C12Q 1/6886* (2006.01)

(57)

**ABSTRACT**

The present invention provides a method for diagnosing and detecting diseases associated with kidney. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in kidney diseases (KCAT) and antibodies binds to KCATs. The present invention provides that KCATs are used as targets for screening agents that modulates the KCAT activities. Further the present invention provides methods for treating diseases associated with kidney.

**Specification includes a Sequence Listing.**